Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2025

Conditions
Non Small Cell Lung Cancer MetastaticAdvanced Melanoma
Interventions
COMBINATION_PRODUCT

FMT + ICI

"This study will include 3 cohorts of patients: (1) Patients with advanced or unresectable NSCLC, (2) patients with advanced or unresectable melanoma, and (3) patients with unresectable or advanced uveal melanoma. Patients with NSCLC, melanoma, uveal melanoma and will be analyzed in three separate subgroups given their differing clinical outcomes.~Each group will be treated with ICI as per their respective first line options, in combination with investigational FMT capsules."

Trial Locations (6)

N6A 5W9

London Health Sciences Centre, London

L1G 8A2

DRCC Lakeridge Health, Oshawa

M4N 3M5

Sunnybrook Health Sciences Centre/Sunnybrook Research Institute, Toronto

H2X 3E4

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

H4A 3J1

McGill University Health Center, Montreal

G1J 1Z4

CHU de Québec, Centre intégré en cancérologie (CIC), Hôpital de L'Enfant-Jésus, Québec

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER